News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Durata Therapeutics, Inc.  (DRTX) Initiates Enrollment In A Phase 3b Study Of Dalvance™ In A 1500 Mg Single Dose


4/24/2014 8:56:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO, April 24, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that it has initiated enrollment of a Phase 3b clinical trial to evaluate the efficacy and safety of its investigational product, Dalvanceā„¢ (dalbavancin) for injection, in a single 1500 milligram dose infused over 30 minutes in adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES